Inclusion Criteria

Criteria for inclusion:

- Patients with a histological or cytological verified adenocarcinoma of the colon or
rectum with non-resectable or metastatic cancer.

- Patients with measurable disease without previous radiotherapy

- Patients with metastatic colorectal cancer with progression after previous therapy
with 5-fluoropyrimidines, oxaliplatin or irinotecan. Patients should have been
treated with oxaliplatin, but if oxaliplatin has be contraindicated or not tolerated
the patient can participate in the trial.

- Patients with KRAS-mutation in their primary tumour or metastasis.

- Patients with progression after therapy with irinotecan or cetuximab independent of
KRAS mutation status.

- Previous radiotherapy is allowed to less than 25 % of the bone marrow.

- Age more or equal to 18 years.

- Performance status less than 3.

- An expected survival time of at least 3 months.

- Signed informed consent according to specifications from the ethical comites.

Criteria for exclusion:

- Former or other concurrent malignant disease except treated basal cell carcinoma or
in situ cervical cancer.

- No cytotoxic therapy or other experimental treatment within 28 days before inclusion.

- No former therapy with everolimus or other rapamycin as sirolimus or temsirolimus.

- No known hypersensitivity for one or more components in the therapy.

- No uncontrolled diabetes

- No serious non-healing wounds, gastric ulcers, bone fractures, greater surgical
procedures, major traumatic injuries within 28 days before inclusion.

- No ongoing bleeding or pathological condition associated with a risk of bleeding.

- No liver disease as cirrhose, chronical active hepatitis or chronic persistent
hepatitis.

- No gastrointestinal disturbances in function that might cause a major change in the
absorption of everolimus as ulcerative disease, uncontrolled nausea, vomiting,
diarrhoea, malabsorption syndrome.

- No planned immunisation with attenuated virus in the study period.

- Patients that is unable to follow treatment or evaluation plan.

- Every condition or therapy that after the judgement of investigator might infer the
patient a risk or influence the trials objective.

- Pregnant or breastfeeding women.

- At fertile women this is insured by a negative test of pregnancy or use of a safe
anticonception during the trial period and at least 3 months after end of treatment.

- Patients with active infections or other serious medical co-morbidity, that might
prevent the patient from being treated with the protocoled therapy.

- Incapacitated